CN103585194B - 通经草提取物在制备治疗艾滋病药物中的应用 - Google Patents
通经草提取物在制备治疗艾滋病药物中的应用 Download PDFInfo
- Publication number
- CN103585194B CN103585194B CN201310525452.7A CN201310525452A CN103585194B CN 103585194 B CN103585194 B CN 103585194B CN 201310525452 A CN201310525452 A CN 201310525452A CN 103585194 B CN103585194 B CN 103585194B
- Authority
- CN
- China
- Prior art keywords
- gmel
- aleuritopteris argentea
- fee
- extract
- fee extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000688694 Cheilanthes argentea Species 0.000 title claims abstract description 106
- 239000000284 extract Substances 0.000 title claims abstract description 79
- 239000003814 drug Substances 0.000 title claims abstract description 50
- 208000030507 AIDS Diseases 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 238000011282 treatment Methods 0.000 title claims abstract description 24
- 239000011347 resin Substances 0.000 claims abstract description 12
- 229920005989 resin Polymers 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 239000007788 liquid Substances 0.000 claims description 24
- 238000000605 extraction Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 13
- 230000000274 adsorptive effect Effects 0.000 claims description 7
- 230000001476 alcoholic effect Effects 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003463 adsorbent Substances 0.000 abstract description 5
- 238000001228 spectrum Methods 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 3
- 238000002481 ethanol extraction Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 241000700605 Viruses Species 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 14
- BZYOCVKVXZEFJW-UHFFFAOYSA-N 5,7-dihydroxy-2-(3-methoxyphenyl)-6,8-dimethyl-2,3-dihydrochromen-4-one Chemical compound COC1=CC=CC(C2OC3=C(C)C(O)=C(C)C(O)=C3C(=O)C2)=C1 BZYOCVKVXZEFJW-UHFFFAOYSA-N 0.000 description 12
- 241000725303 Human immunodeficiency virus Species 0.000 description 12
- LTVBTVOAUQJJEV-UHFFFAOYSA-N 4-methylindeno[1,2-b]pyridin-5-one Chemical compound C12=CC=CC=C2C(=O)C2=C1N=CC=C2C LTVBTVOAUQJJEV-UHFFFAOYSA-N 0.000 description 11
- UVPBNPUZWAOBQX-UHFFFAOYSA-N Sarotanoside Natural products OC1C(O)C(O)C(C)OC1OC1C(OC=2C=C3OC(CC(=O)C3=C(O)C=2)C=2C=CC=CC=2)OC(CO)C(O)C1O UVPBNPUZWAOBQX-UHFFFAOYSA-N 0.000 description 11
- 208000011580 syndromic disease Diseases 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241001453658 Onychium japonicum Species 0.000 description 8
- 229930003949 flavanone Natural products 0.000 description 8
- 150000002208 flavanones Chemical class 0.000 description 8
- 235000011981 flavanones Nutrition 0.000 description 8
- 229930182470 glycoside Natural products 0.000 description 8
- 229960002555 zidovudine Drugs 0.000 description 8
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- HAIHGFWQOPJMPV-UHFFFAOYSA-N (S)-5,7-Dihydroxy-6,8-dimethylflavanone Chemical compound C1C(=O)C2=C(O)C(C)=C(O)C(C)=C2OC1C1=CC=CC=C1 HAIHGFWQOPJMPV-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- -1 flavone compound Chemical class 0.000 description 4
- 150000002338 glycosides Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 239000005723 virus inoculator Substances 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- LNWOKEZJIRLIDO-ZJGHDVHGSA-N (E)-5-[(1S,4aR,6S,8aR)-6-hydroxy-5,5,8a-trimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]-3-methylpent-2-enoic acid Chemical compound CC1(C)[C@@H](O)CC[C@]2(C)[C@@H](CCC(/C)=C/C(O)=O)C(=C)CC[C@H]21 LNWOKEZJIRLIDO-ZJGHDVHGSA-N 0.000 description 2
- LNWOKEZJIRLIDO-UHFFFAOYSA-N 15-Carboxylic acid-(ent-3beta,13Z)-8(17),13-Labdadien-3,15-diol Natural products CC1(C)C(O)CCC2(C)C(CCC(C)=CC(O)=O)C(=C)CCC21 LNWOKEZJIRLIDO-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000031957 HIV carrier Diseases 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229940076263 indole Drugs 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229960001627 lamivudine Drugs 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 229960000311 ritonavir Drugs 0.000 description 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 2
- 229960001852 saquinavir Drugs 0.000 description 2
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 229940124321 AIDS medicine Drugs 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 208000029224 Thoracic injury Diseases 0.000 description 1
- 108010021119 Trichosanthin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940124524 integrase inhibitor Drugs 0.000 description 1
- 239000002850 integrase inhibitor Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000000627 locus coeruleus Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310525452.7A CN103585194B (zh) | 2013-10-31 | 2013-10-31 | 通经草提取物在制备治疗艾滋病药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310525452.7A CN103585194B (zh) | 2013-10-31 | 2013-10-31 | 通经草提取物在制备治疗艾滋病药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103585194A CN103585194A (zh) | 2014-02-19 |
CN103585194B true CN103585194B (zh) | 2015-10-28 |
Family
ID=50075648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310525452.7A Expired - Fee Related CN103585194B (zh) | 2013-10-31 | 2013-10-31 | 通经草提取物在制备治疗艾滋病药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103585194B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105061150B (zh) * | 2015-08-03 | 2017-12-08 | 河北科技大学 | 一种新型二萜醇、其制备方法及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1210715A (zh) * | 1997-09-09 | 1999-03-17 | 衡阳医学院 | 一种治疗恶性肿瘤的药物 |
CN1435181A (zh) * | 2002-01-31 | 2003-08-13 | 南华大学 | 金粉蕨素在制备治疗或预防心血管疾病药物中的应用 |
CN1615922A (zh) * | 2003-11-15 | 2005-05-18 | 胡硕泉 | 治疗再生障碍性贫血的中草药剂 |
-
2013
- 2013-10-31 CN CN201310525452.7A patent/CN103585194B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1210715A (zh) * | 1997-09-09 | 1999-03-17 | 衡阳医学院 | 一种治疗恶性肿瘤的药物 |
CN1435181A (zh) * | 2002-01-31 | 2003-08-13 | 南华大学 | 金粉蕨素在制备治疗或预防心血管疾病药物中的应用 |
CN1615922A (zh) * | 2003-11-15 | 2005-05-18 | 胡硕泉 | 治疗再生障碍性贫血的中草药剂 |
Non-Patent Citations (4)
Title |
---|
"蒙药通经草的化学成分研究";莎日娜;《万方数据》;20080925;全文 * |
"通经草的化学成分与质量控制方法研究";赵迎春;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》;20111215(第S2期);1-47 * |
"通经草的化学成分研究";赵迎春等;《中草药》;20090731;第40卷(第7期);1043-1045 * |
"通经草黄酮的体外抗氧化性";包玉敏等;《光谱实验室》;20081130;第25卷(第6期);1031-1034 * |
Also Published As
Publication number | Publication date |
---|---|
CN103585194A (zh) | 2014-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100453094C (zh) | 中药复方通脉口服液有效部位的药物组合物及其制备方法 | |
CN108752497B (zh) | 巴戟天水提物、寡糖和多糖制备,及其应用 | |
CN102138966B (zh) | 藏茵陈提取物及其制备方法、药物组合物和用途 | |
CN101721488B (zh) | 一种治疗肝病的药物组合物及其制备方法 | |
CN102210737B (zh) | 一种红薯叶提取物、其制备方法及应用 | |
CN1813711B (zh) | 一种异黄酮类化合物的用途 | |
CN102670631A (zh) | 一种四楞麻总苯乙醇苷组合物、制备方法及应用 | |
CN104887813B (zh) | 五味子醇提物及其在制备抗肝纤维化药物中的应用 | |
CN101824014A (zh) | 银线草中具抗肿瘤活性的化合物及其有效部位和用途 | |
CN101028317B (zh) | 地耳草在制备防治肾功能不全的药物中的应用 | |
CN103585194B (zh) | 通经草提取物在制备治疗艾滋病药物中的应用 | |
WO2002102308A2 (en) | Pharmaceutical composition for the treatment of viral infection | |
CN100584345C (zh) | 具抗病毒作用的小紫金牛提取物及其提取方法和应用 | |
CN109966339B (zh) | 一种具有抗hbv病毒作用的苦豆子有效部位及制法与应用 | |
ES2456709T3 (es) | Preparación medicinal que contiene glicósidos feniletanoides extraídos de Cistanche tubulosa | |
CN103588834B (zh) | 金粉蕨素的提取制备方法及其应用 | |
CN104983789A (zh) | 异叶青兰活性精细组分的分离方法及其应用 | |
CN103585223B (zh) | 毛莲菜提取物在制备治疗艾滋病药物中的应用 | |
CN103610798A (zh) | 一种白花蛇舌草的活性部位及其制备方法、应用 | |
CN103585212B (zh) | 阿莫尼亚脂提取物在制备治疗艾滋病药物中的应用 | |
CN103393738B (zh) | 一种防治甲型h1n1流感病毒的中药组合物 | |
CN103110677B (zh) | 一种西洋参提取物的制备方法及其在制备防治艾滋病药物中的应用 | |
CN114668773B (zh) | 重楼提取物在抗克里米亚刚果出血热病毒中的应用 | |
CN101322782B (zh) | 禹白附抗艾滋病的新用途及其有效部位的提取分离方法 | |
CN109771465B (zh) | 一种具有显著抑制hiv/siv作用的中药有效部位组合 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SUN CHENGYONG Free format text: FORMER OWNER: JINAN XINGYI MEDICAL TECHNOLOGY CO., LTD. Effective date: 20150910 Owner name: SUN XIAOHONG Effective date: 20150910 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Sun Chengyong Inventor after: Wang Meihua Inventor after: Sun Xiaohong Inventor before: Kong Qianqian |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: KONG QIANQIAN TO: SUN CHENGYONG WANG MEIHUA SUN XIAOHONG |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20150910 Address after: 502, room 2, unit 3, building 23, Yongan Road, Shouguang Road, Shouguang, Shandong, Weifang 262750, China Applicant after: Sun Chengyong Applicant after: Sun Xiaohong Address before: 250101 No. 51 Industrial South Road, Ji'nan hi tech Zone, Shandong, Ji'nan Applicant before: Jinan Xingyi Medical Technology Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151028 Termination date: 20171031 |
|
CF01 | Termination of patent right due to non-payment of annual fee |